U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917546) titled 'Early COMT Inhibition in PD' on Oct. 20.
Brief Summary: This prospective, randomized, assessor-blinded, parallel-group clinical trial aims to compare the effectiveness of early add-on opicapone versus levodopa dose escalation in patients with Parkinson's disease experiencing emerging motor fluctuations.
A total of 46 patients are randomly assigned (1:1) to receive either opicapone 50 mg once daily in addition to their existing dopaminergic treatment or an additional daily dose of levodopa/dopa-decarboxylase inhibitor (100-200 mg).
Treatment effects are assessed over approximately four weeks through standardized clinical evaluations...